{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:57:57Z","timestamp":1790449077739,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"DOI":"10.1007\/s12328-026-02458-2","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:21:24Z","timestamp":1790400084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to pembrolizumab after progression on durvalumab in cholangiocarcinoma: a case report of immune checkpoint inhibitor switching"],"prefix":"10.1007","author":[{"given":"Akito","family":"Furuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-0052","authenticated-orcid":false,"given":"Masatoshi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Teramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2458_CR1","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"2458_CR2","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet"},{"key":"2458_CR3","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ueg2.12656","volume":"12","author":"K Mitzlaff","year":"2024","unstructured":"Mitzlaff K, Kirstein MM, M\u00fcller C, et al. Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real-world cohort. United Eur Gastroenterol J. 2024;12:1230\u201342.","journal-title":"United Eur Gastroenterol J"},{"key":"2458_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11523-024-01044-1","volume":"19","author":"A Olkus","year":"2024","unstructured":"Olkus A, Tomczak A, Berger A, et al. Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of real-world data. Target Oncol. 2024;19:213\u201321.","journal-title":"Target Oncol"},{"key":"2458_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43:1803\u201312.","journal-title":"Liver Int"},{"key":"2458_CR6","doi-asserted-by":"publisher","first-page":"114199","DOI":"10.1016\/j.ejca.2024.114199","volume":"208","author":"M Rimini","year":"2024","unstructured":"Rimini M, Fornaro L, Rizzato M, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population. Eur J Cancer. 2024;208:114199.","journal-title":"Eur J Cancer"},{"key":"2458_CR7","doi-asserted-by":"publisher","first-page":"1493234","DOI":"10.3389\/fimmu.2025.1493234","volume":"16","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Guo J, Ren T, et al. Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study. Front Immunol. 2025;16:1493234.","journal-title":"Front Immunol"},{"key":"2458_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00432-025-06239-1","volume":"151","author":"F Gerhardt","year":"2025","unstructured":"Gerhardt F, M\u00fcller C, Venerito M, et al. Treatment with gemcitabine\/cisplatin and durvalumab for advanced biliary tract cancer: real-world data from a multicenter German patient population. J Cancer Res Clin Oncol. 2025;151:191.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2458_CR9","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1007\/s12072-024-10728-9","volume":"18","author":"KC Lai","year":"2024","unstructured":"Lai KC, Chen YH, Hung YP, et al. Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy. Hepatol Int. 2024;18:1804\u201314.","journal-title":"Hepatol Int"},{"key":"2458_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/1759-7714.13824","volume":"12","author":"N Furuya","year":"2021","unstructured":"Furuya N, Nishino M, Wakuda K, et al. Real-world efficacy of atezolizumab in non-small cell lung cancer: a multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. Thorac Cancer. 2021;12:613\u201318.","journal-title":"Thorac Cancer"},{"key":"2458_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/1759-7714.13241","volume":"11","author":"K Fujita","year":"2020","unstructured":"Fujita K, Yamamoto Y, Kanai O, et al. Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody. Thorac Cancer. 2020;11:15\u20138.","journal-title":"Thorac Cancer"},{"key":"2458_CR12","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.21873\/anticanres.13543","volume":"39","author":"K Fujita","year":"2019","unstructured":"Fujita K, Uchida N, Yamamoto Y, et al. Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Res. 2019;39:3917\u201321.","journal-title":"Anticancer Res"},{"key":"2458_CR13","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/1759-7714.13483","volume":"11","author":"S Kitagawa","year":"2020","unstructured":"Kitagawa S, Hakozaki T, Kitadai R, et al. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020;11:1927\u201333.","journal-title":"Thorac Cancer"},{"key":"2458_CR14","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/j.clml.2022.06.004","volume":"22","author":"SK Thiruvengadam","year":"2022","unstructured":"Thiruvengadam SK, Mei MG, Godfrey J, et al. PD-1 blockade after avelumab in relapsed\/refractory classical Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22:e893\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2458_CR15","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.21037\/tlcr-22-140","volume":"11","author":"Z Cai","year":"2022","unstructured":"Cai Z, Zhan P, Song Y, et al. Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2022;11:1555.","journal-title":"Transl Lung Cancer Res"},{"key":"2458_CR16","first-page":"e12","volume":"16","author":"A Sasaki","year":"2024","unstructured":"Sasaki A, Matsuda K, Okamoto R. Exceptional response to pembrolizumab following durvalumab failure in a patient with microsatellite instability-high cholangiocarcinoma. Cureus. 2024;16:e12.","journal-title":"Cureus"},{"key":"2458_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2020","unstructured":"Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6:375\u201384.","journal-title":"JAMA Oncol"},{"key":"2458_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s43018-023-00712-x","volume":"5","author":"S Chaib","year":"2024","unstructured":"Chaib S, L\u00f3pez-Dom\u00ednguez JA, Lalinde-Guti\u00e9rrez M, et al. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nat Cancer. 2024;5:448\u201362.","journal-title":"Nat Cancer"},{"key":"2458_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40360-020-00404-7","volume":"21","author":"K Nishino","year":"2020","unstructured":"Nishino K, Kunimasa K, Kimura M, et al. Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report. BMC Pharmacol Toxicol. 2020;21:26.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2458_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06026-3","volume":"617","author":"JS Park","year":"2023","unstructured":"Park JS, Gazzaniga FS, Wu M, et al. Targeting PD-L2\u2013RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023;617:377\u201385.","journal-title":"Nature"},{"key":"2458_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s12328-023-01833-7","volume":"16","author":"H Matsubayashi","year":"2023","unstructured":"Matsubayashi H, Todaka A, Ishiwatari H, et al. Discordant microsatellite instability findings in two samples from a patient with biliary cancer that responded to pembrolizumab. Clin J Gastroenterol. 2023;16:748\u201354.","journal-title":"Clin J Gastroenterol"},{"key":"2458_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"2458_CR23","doi-asserted-by":"publisher","first-page":"153303382110623","DOI":"10.1177\/15330338211062324","volume":"20","author":"H Kim","year":"2021","unstructured":"Kim H, Kim H, Kim R, et al. Tumor mutational burden as a biomarker for advanced biliary tract cancer. Technol Cancer Res Treat. 2021;20:15330338211062324.","journal-title":"Technol Cancer Res Treat"},{"key":"2458_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pili\u00e9 PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32:661\u201372.","journal-title":"Ann Oncol"},{"key":"2458_CR25","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1056\/NEJMc2031965","volume":"384","author":"B Rousseau","year":"2021","unstructured":"Rousseau B, Foote MB, Maron SB, et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N Engl J Med. 2021;384:1168\u201370.","journal-title":"N Engl J Med"},{"key":"2458_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5811\/WESTJEM.20305","volume":"26","author":"C Li","year":"2025","unstructured":"Li C, Faiz SA, Boysen-Osborn M, et al. Immune checkpoint inhibitor-associated pneumonitis: a narrative review. West J Emerg Med. 2025;26:210.","journal-title":"West J Emerg Med"},{"key":"2458_CR27","unstructured":"Banavasi H, Kim S, Alkassis S et al. Immune checkpoint inhibitor-induced pneumonitis: incidence, clinical characteristics, and outcomes. Hematol Oncol Stem Cell Ther. 2021."},{"key":"2458_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709\u201317.","journal-title":"J Clin Oncol"},{"key":"2458_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152:271\u201381.","journal-title":"Chest"},{"key":"2458_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00262-026-04375-2","volume":"75","author":"K Masumoto","year":"2026","unstructured":"Masumoto K, Tsubouchi K, Matsukane R, et al. Clinical characteristics, prognostic factors, and feasibility of ICI continuation in immune checkpoint inhibitor-related pneumonitis. Cancer Immunol Immunother. 2026;75:123.","journal-title":"Cancer Immunol Immunother"},{"key":"2458_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865\u201371.","journal-title":"JAMA Oncol"},{"key":"2458_CR32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","volume":"6","author":"FC Santini","year":"2018","unstructured":"Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018;6:1093\u20139.","journal-title":"Cancer Immunol Res"},{"key":"2458_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3389\/fonc.2019.01437","volume":"9","author":"X Liang","year":"2019","unstructured":"Liang X, Guan Y, Zhang B, et al. Severe immune-related pneumonitis with PD-1 inhibitor after progression on previous PD-L1 inhibitor in small cell lung cancer: a case report and review of the literature. Front Oncol. 2019;9:1437.","journal-title":"Front Oncol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02458-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02458-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02458-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:01:53Z","timestamp":1790445713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02458-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":33,"alternative-id":["2458"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02458-2","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Human\/animal rights","group":{"name":"EthicsHeading","label":"Declarations"}}]}}